(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.53%.
Passage Bio's earnings in 2026 is -$45,264,000.On average, 7 Wall Street analysts forecast PASG's earnings for 2026 to be -$16,016,884, with the lowest PASG earnings forecast at -$23,363,519, and the highest PASG earnings forecast at -$10,647,089. On average, 6 Wall Street analysts forecast PASG's earnings for 2027 to be -$11,564,147, with the lowest PASG earnings forecast at -$17,538,215, and the highest PASG earnings forecast at -$4,806,210.
In 2028, PASG is forecast to generate -$1,361,759 in earnings, with the lowest earnings forecast at -$6,977,904 and the highest earnings forecast at $7,342,820.